Article Sidebar

PDF
Date Published: 15/02/2023
Abstract Views: 168
Views PDF: 88
DOI: https://doi.org/10.51298/vmj.v521i2.4049
Issue
Vol. 521 No. 2 (2022)
Section
Các bài báo
How to Cite
Đỗ, H. K., & Đào, M. T. (2023). EVALUATING THE RESULTS OF ADJUVANT CHEMOTHERAPY OF PEMETREXED PLUS CARBOPLATIN IN PATIENTS WITH STAGE IB-IIIA NON-SQUAMOUS NON-SMALL CELL LUNG CANCER. Vietnam Medical Journal, 521(2). https://doi.org/10.51298/vmj.v521i2.4049

EVALUATING THE RESULTS OF ADJUVANT CHEMOTHERAPY OF PEMETREXED PLUS CARBOPLATIN IN PATIENTS WITH STAGE IB-IIIA NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

Hùng Kiên Đỗ1,, Minh Thế Đào1
1 National Cancer Hospital

Main Article Content

Abstract

Objectives: Evaluating disease-free survival and toxicity of adjuvant chemotherapy with pemetrexed - carboplatin in patients with stage IB-IIIA non-squamous non small cell lung cancer. Patients and method: Uncontrolled clinical interventional study including 38 patients with stage IB-IIIA non-squamous NCSLC who had radical surgery at the K hospital and received 4 cycles of pemetrexed-carboplatin adjuvant treatment between January 2020 and May 2022. Results: The mean disease-free survival (DFS) was 27.9 ± 1.2 months. The 2-year DFS rate is 65%. The median DFS has not been reached. The treatment completion rate was 94.7%. Common hematologic toxicities were neutropenia (63.2%) and thrombocytopenia (52.6%). Common non-hematological toxicities were vomiting, nausea (71.1%) and fatigue (57.9%), mainly grades 1 and 2. Rarely reported high-altitude toxicity. Conclusion: Pemetrexed - carboplatin adjuvant chemotherapy for NCSLC has a high disease-free survival rate that is equivalent to that of presently utilized chemotherapy regimens that incorporate cisplatin. Low toxicity and good tolerability characterize the regimen.

Article Details

Keywords

Non-small cell lung cancer, pemetrexed / carboplatin, adjuvant chemotherapy.

References

1. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589–2597
2. Ravdin PM, Davis G. Prognosis of patients with resected non-small cell lung cancer: impact of clinical and pathologic variables. Lung Cancer. 2006; 52:207–212
3. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552–3559.
4. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2004;22:3852–3859.
5. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99:847–857.
6. Trần Đình Anh, Trần Văn Thuấn, Đỗ Hùng Kiên. Đánh giá kết quả điều trị hóa chất bổ trợ phác đồ Vinorelbin - Cisplatin trong ung thư phổi không tế bào nhỏ giai đoạn IB-IIIA. Tạp chí y học Việt Nam 2019; 481: 115-119
7. Đào Thị Thanh Nhàn, Nguyễn Tiến Quang, Nguyễn Thị Hương Giang. Đánh giá kết quả hóa trị bổ trợ phác đồ Pemetrexed - Cisplatin trên bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn IB-IIIA. Tạp chí y học Việt Nam 2020; 494: 187-190
8. Kreuter M., Vansteenkiste J., Fischer J.R., et al. (2016).Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study). J Thorac Oncol Off Publ Int Assoc Study Lung Cancer, 11(1), 85–93.
9. Zhang L, Ou W, Liu Q, et al. Pemetrexed plus carboplatin as adjuvant chemotherapy in patients with curative resected non-squamous non-small cell lung cancer.Thorac Cancer 2014;5:50-56.